Opticyte Revenue and Competitors

Location

$5.7M

Total Funding

Estimated Revenue & Valuation

  • Opticyte's estimated annual revenue is currently $1.3M per year.(i)
  • Opticyte's estimated revenue per employee is $125,500
  • Opticyte's total funding is $5.7M.

Employee Data

  • Opticyte has 10 Employees.(i)
  • Opticyte grew their employee count by 43% last year.

Opticyte's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
Director Clinical AffairsReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.9M39117%$14.9MN/A
#2
$44.9M143-30%$211.3MN/A
#3
$54M17211%$35.5MN/A
#4
$4.3M17-19%N/AN/A
#5
$18.3M73N/AN/AN/A
#6
$8.3M336%N/AN/A
#7
$81.1M32317%N/AN/A
#8
$7M28-12%N/AN/A
#9
$204.8M8163%N/AN/A
#10
$6.3M5025%$27.5MN/A
Add Company

What Is Opticyte?

At Opticyte, we are committed to transforming the standard of care for the leading causes of organ failure, including sepsis. The problem is massive, is expensive to treat, and leads to one death every 2.8 seconds globally. Current technologies including pulse oximeters fail to provide clinicians with the definitive data they need to diagnose, monitor, and treat patients in real-time, when they have the best chance of preventing organ failure. Opticyte's Cell O2 Monitor is the first and only single solution to provide definitive, continuous, and actionable insights for this critical unmet need. Opticyte's executive and advisory team includes pioneers in new optical spectroscopy and multivariate analysis technology, leaders in medical device commercialization, and medical clinicians. The company’s early funding successes, research validation, and product development milestones provide credibility and reinforce our position as a disruptive medical device innovator.

keywords:N/A

$5.7M

Total Funding

10

Number of Employees

$1.3M

Revenue (est)

43%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Opticyte News

2022-03-22 - Study in Modern Optometry Shows Effectiveness Of Merakris Therapeutics’ Eye Product, Opticyte® Matrix

Merakris Therapeutics, Inc. RESEARCH TRIANGLE PARK, N.C., March 24, 2022 (GLOBE NEWSWIRE) -- Opticyte® Amniotic Ocular Matrix, a product of...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$2M100%N/A
#2
$1.5M10-89%N/A
#3
$17.5M10-33%$221M
#4
$0.9M10N/AN/A
#5
$0.9M10N/AN/A